Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement
Combined company will operate under the name 'Pelthos Therapeutics Inc.' and will trade on the NYSE American exchange under the ticker symbol 'PTHS' starting on July 2, 2025
DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Merger Sub Inc. ('Merger Sub'), a wholly owned subsidiary of Channel Therapeutics Corporation ('Channel'), merged with and into LNHC, Inc. ('LNHC'), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated ('Ligand') (Nasdaq: LGND), with LNHC surviving as a wholly owned subsidiary of Channel (the 'Merger'). The combined company will operate under the name Pelthos Therapeutics Inc. ('Pelthos' or the 'Company'), and its shares will trade on the NYSE American exchange starting on July 2, 2025 under the new ticker symbol 'PTHS'.
'This Merger represents a significant milestone for Pelthos, taking us closer to the launch of ZELSUVMI™ and enabling us to deliver this innovative product to the patients who need it. We are excited to begin this new chapter as a publicly traded company and to create value for our shareholders,' said Scott Plesha, the CEO of the Company following the Merger.
Concurrent with the Merger, Pelthos closed on a $50.1 million private placement from a group of strategic investors led by Murchinson Ltd. ('Investors'). The capital is being invested into Pelthos' shares of Series A Convertible Preferred Stock, par value $0.0001 per share (the 'Series A Preferred Stock') and common stock, par value $0.01, and includes cancellation of approximately $18.8 million in bridge capital that has been advanced to Pelthos by certain of the private placement Investors since the beginning of 2025 to support the commercial launch of ZELSUVMI™.
Pelthos will initially focus on the launch and commercialization of ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum infections ('molluscum') in adults and pediatric patients one year of age and older.1 ZELSUVMI™ is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians, afflicting an estimated 16.7 million people in the United States.2,3
Additionally, Pelthos is continuing to evaluate the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Frank Knuettel II, former CEO of Channel Therapeutics Corporation and the newly appointed CFO of Pelthos, added, 'I am pleased to have completed the Merger on behalf of Channel's shareholders, and I am delighted to join the high-caliber team at Pelthos to help guide the launch of ZELSUVMI™. The management team has extensive experience in successfully launching new therapies, and I believe this transaction will position Pelthos for future growth.'
A.G.P. / Alliance Global Partners served as financial advisor to Channel. Sullivan & Worcester LLP served as Channel's legal counsel and Latham & Watkins LLP served as lead counsel to Ligand. Kelley Drye & Warren LLP and Morgan, Lewis and Bockius LLP represented Murchinson Ltd.
About ZELSUVMI™ (berdazimer) topical gel, 10.3%ZELSUVMI™ (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI™ received a novel drug designation from the U.S. Food and Drug Administration in 2024 and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician's office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using Pelthos' proprietary nitric oxide-based technology platform, NITRICIL™. Complete prescribing information and important safety information is available at www.zelsuvmi.com.
About Pelthos Therapeutics Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company's lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.
Forward-Looking Statements This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos' current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as 'plans,' 'believes,' 'expects,' 'anticipates,' and 'will,' and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that investors should feel encouraged that Pelthos has a strong development path towards successfully launching drugs with considerable market opportunities, (ii) the timing of clinical and regulatory events of us and our partners, (iii) the timing of the initiation or completion of preclinical studies and clinical trials by us and our partners; (iv) the timing of product launches, including ZELSUVMI; (v) guidance regarding projected financial results for 2025 and beyond, (vi) the anticipated benefits of the Merger between LNHC and Channel and (vii) the combined company's opportunities, strategy and plans following the Merger. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the combined company's Common Stock will be indicative of the combined company's value or that the combined company's Common Stock will become an attractive investment in the future; we may rely on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue; we and our partners may not be able to timely or successfully advance any product(s) in our internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
Contacts
Pelthos Investor Inquiries: Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com
1 Please see ZELSUVMI™ (berdazimer) topical gel full prescribing information available at https://www.fda.gov/drugsatfda for important safety information or www.zelsuvmi.com2 US Census Bureau. QuickFacts: United States.2022. https://www.census.gov/quickfacts/fact/table/US/PST045222 3 Hebert AA, et al. J Clin Aesthet Dermatol. 2023 Aug;16(8 Suppl 1):S4-S11
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Why Rosenblatt Still Likes Coherent (COHR) Despite Competitive Pressure
Coherent Corp. (NYSE:COHR) is one of the . On August 14, Rosenblatt lowered the firm's price target on the stock to $135 from $150 and kept a Buy rating on the shares. The rating affirmation follows Coherent's fiscal Q4 report. According to Rosenblatt, the company tends to guide conservatively. However, it does not see any fundamental impairment to the positive thesis following the earnings report. The firm did acknowledge that competitor Lumentum has gained steam with its stronger near-term performance in laser chip, OCS, and CPO sales categories. 'We would note that Coherent management tends to guide conservatively. We do not think there is a fundamental impairment to the positive thesis. Lumentum has grabbed the momentum with stronger relative near-term performance in laser chip, OCS, and CPO sales. Nevertheless, we like the industry thesis and competitive environment, and think both LITE and COHR will do well.' A financial analyst poring over market data, projecting the company's futur investments. Even though Coherent is subject to this competitive pressure, Rosenblatt anticipates it to 'catch up in these key AI Optical categories over the course of FY26 and into FY27.' Moreover, it believes both Lumentum and Coherent will execute well in the industry. Coherent Corp. (NYSE:COHR) is an American manufacturer of optical materials and semiconductors. While we acknowledge the potential of COHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
If You'd Invested $100 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Investors are beginning to see Palantir as more than a niche government contractor. Palantir achieved its first $1 billion quarter in the second quarter. Investors should be wary of Palantir's extremely high valuation. 10 stocks we like better than Palantir Technologies › Artificial intelligence (AI) software company Palantir (NASDAQ: PLTR) has a strong case as the most talked-about stock this year. The success of its AI tools amid the current AI boom has made it one of the more high-profile stocks on the market, and its stock price has followed the hype. Its stock is up 143% year to date through Aug. 14, but the surge started way before now. Had you invested $100 into the stock three years ago (with Aug. 14, 2022, as the starting point), your investment would be worth over $1,850. Calling those returns impressive would undoubtedly be an understatement. What has changed with Palantir's business? Palantir's core business hasn't changed over the past three years, but the surrounding perception seemingly has. For a while, many people viewed Palantir as a niche government contractor, but it is now seen as a company whose software can be used for commercial businesses as well. In the second quarter, Palantir achieved its first $1 billion quarter (up 48% year over year), with its U.S. government and U.S. commercial benefits increasing revenue 53% and 93% year over year, respectively. After such an impressive run over the past three years, the one red flag with Palantir's stock is just how expensive it has become. At the time of this writing, the stock is trading at nearly 135 times its sales, which is, to put it lightly, absurd by even the most lax of standards. Palantir has proven it's a great company and leader in its industry, but if you're investing expecting similar returns over the next three years, you could be in for some disappointment. If you're interested in investing in the company, make sure you approach it with a long-term mindset, and mentally prep yourself for the inevitable volatility. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. If You'd Invested $100 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
3 minutes ago
- Yahoo
Rosenblatt Trims Palo Alto Networks (PANW) Price Target to $215, Keeps Buy Rating
Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the AI Stocks Making Headlines This Week. On August 14, Rosenblatt lowered the firm's price target on the stock to $215 from $235 and kept a Buy rating on the shares. According to the firm, channel checks reveal steady fourth-quarter performance for Palo Alto Networks. 'Recent channel checks indicate steady Q4 performance for Palo Alto Networks, with ongoing momentum across software firewalls, firewall refresh, SASE, and continued uptake of XSIAM.' Rosenblatt affirmed that SASE, specifically Prisma Access, is experiencing customer expansion as organizations look to consolidate security services. The new Prisma Access Browser is gaining traction now that customers are increasingly looking to secure GenAI app usage and browser-based workflows. Pixabay/Public Domain 'XSIAM adoption is supported by competitive conversions from legacy platforms such as QRadar. Renewal activity is contributing to larger multi-product agreements, reflecting ongoing platform integration trends. We expect revenue growth above our and the Street's 14% estimate (FY25 guide: +14.5%), with strength flowing through to better‑than‑expected operating margins and a PF EPS beat. This view is supported by PANW's track record of exceeding Street PF EPS by an average 5.1% over the last four quarters. Maintaining Buy rating, lowering PT to $215 (from $235) on reduced FY26 estimates. Our PT of $225 applies 13.5x EV/CY26e Sales (vs. 14.4x prior), reflecting 12.5% growth.' Palo Alto Networks, Inc. (NASDAQ:PANW) is a leader in AI-powered cybersecurity. While we acknowledge the potential of PANW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
